In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 1, 1999, Pages 81-87

  Chien, Mark ^a   Astumian, Mary ^a   Liebowitz, David ^a   Rinker Schaeffer, Carrie ^a   Stadler, Walter M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apoptosis; Cyclin dependent kinase; Cytotoxicity; Multidrug resistance

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE; DOXORUBICIN; FLAVOPIRIDOL; MULTIDRUG RESISTANCE PROTEIN;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CELL CYCLE; CHEMOSENSITIVITY; CYTOTOXICITY; FLUORESCENCE ACTIVATED CELL SORTER; GROWTH INHIBITION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL LINE; CISPLATIN; COMBINED MODALITY THERAPY; DRUG RESISTANCE, MULTIPLE; FLAVONOIDS; GENES, TUMOR SUPPRESSOR; HUMANS; PIPERIDINES; RADIOTHERAPY; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0002128714     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050948     Document Type: Article

References (22)

1. Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, Greene JF Jr, Koss W, Morgan CD, Stinson SF, Siford TJ, Alvord WG, Klabansky RL, Sausville EA (1998) Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91: 2482-2490
2. Bible KC, Kaufmann SH (1996) Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56: 4856-4861
3. Bible KC, Kaufmann SH (1997) Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineo-plastic agents: the importance of sequence of administration. Cancer Res 57: 3375-3380
4. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ (1996) Flavopiridol induces G1 arrest with inhibition of cyclin dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973-2978
5. Figueira de Azevedo W, Mueller-Dieckmann H-J, Schulze-Gahmen U, Worland PJ, Sausville E, Kim S-H (1996) Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci 93: 2735-2740
6. Hooijberg JH, Broxterman HJ, Heijn M, Fles DL, Lankelma J, Pinedo HM (1997) Modulation by (iso)flavonoids of the AT-Pase activity of the multidrug resistance protein. FEBS Lett 413: 344-348
7. Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E (1992) Growth inhibition and reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84: 1736-1740
8. Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL (1997) The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 90: 4307-4312
9. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD (1992) Altered cell cycle arrest and gene amplification potentially accompany loss of wild-type p53. Cell 70: 923-935
10. Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ (1994) Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 201: 589-595
11. Mosman T (1983) Rapid colorimetric assay for cellular growth and survival. Application to proliferation and cytotoxicity asssays. J Immunol Methods 65: 55
12. O'Connor PM, Jackman J, Bae I, Myers TG et al (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anti-cancer agents. Cancer Res 57: 4285-4300
13. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, Losiewicz MD, Pommier Y, Sausville EA, Senderowicz AM (1998) Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91: 458-465
14. Reznikoff CA, Loretz LJ, Pesciotta DM, Oberley TD, Ignjatovic MM (1987) Growth kinetics and differentiation in vitro of normal human uroepithelial cells on collagen gel substrates in defined medium. J Cell Phys 131: 285-301
15. Reznikoff CA, Belair C, Savelieva E et al (1994) Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev 8: 2227-2240
16. Rieger KM, Little AF, Swart JM, Kastrinakis WV, Fitzgerald JM, Hess DT, Libertino JA, Summerhayes IC (1995) Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br J Cancer 72: 683-690
17. Schinkel AH, Arceci RJ, Smit JJ, Wagenaar E, Baas F, Dolle M, Tsuruo T, Mechetner EB, Roninson IB, Borst P (1993) Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein. Int J Cancer 55: 478-484
18. Schwartz GK, Farsi K, Maslak P, Kelsen DP, Spriggs D (1997) Potentiation of apoptosis by flavopiridol in mitomycin-C treated gastric and breast cancer cells. Clin Cancer Res 3: 1467-1472
19. Sherr CJ (1996) Cancer cell cycles. Science 274: 1672-1677
20. Stadler WM, Olopade OI (1996) The 9p21 region in bladder cancer cell lines: large homozygous deletions inactivate the CDKN2, CDKN2B, and MTAP genes. Urol Res 24: 239-244
21. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem Pharm 46: 1831-1840
22. Yeager TR, Reznikoff CA (1998) Methotrexate resistance in human uroepithelial cells with p53 alterations. J Urol 159: 581-585